Citius Pharma reports FY2025 net loss $39.7M; launches LYMPHIR in December 2025

Citius Pharmaceuticals, Inc.

Net loss $39.7M ($3.38/share) vs $40.2M ($5.97/share) prior year; no revenue.
R&D expenses $9.2M vs $11.9M YoY; G&A $18.5M vs $18.2M YoY.
Raised ~$61M in gross proceeds: $25M at Citius Pharma, $36M at Citius Oncology (CTOR).
LYMPHIR launched in U.S. December 2025 for CTCL; secured NCCN Category 2A and HCPCS J-code.
Cash and equivalents $4.3M at Sep 30, 2025; continued FDA engagement on Mino-Lok and Halo-Lido.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.